AAIC 2025 Abstract·26 DecPrecision Medicine in Alzheimer’s Disease (AD): Observed Efficacy Treatment Effects from Blarcamesine Clinical AD TrialsTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecA Patient‐Centric, Digital Multimodal Post‐Market Approval Continuous Monitoring of Drug Safety & Efficacy Platform for BlarcamesineAI & dataPaper
AAIC 2025 Abstract·26 DecPhase IIb/III ATTENTION‐AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease PatientsTrial in peopleInterventionsPaper